Guardant Health, Inc. (GH)

$32.55

-1.28

(-3.78%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $32.02
    $33.74
    $32.55
    downward going graph

    1.63%

    Downside

    Day's Volatility :5.08%

    Upside

    3.51%

    downward going graph
  • $15.81
    $41.06
    $32.55
    downward going graph

    51.43%

    Downside

    52 Weeks Volatility :61.5%

    Upside

    20.73%

    downward going graph

Returns

PeriodGuardant Health, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
95.26%
8.7%
0.0%
6 Months
37.4%
8.0%
0.0%
1 Year
-14.07%
14.0%
0.0%
3 Years
-72.14%
17.0%
-18.2%

Highlights

Market Capitalization
4.1B
Book Value
$0.56
Earnings Per Share (EPS)
-3.92
Wall Street Target Price
36.37
Profit Margin
-76.34%
Operating Margin TTM
-59.16%
Return On Assets TTM
-17.29%
Return On Equity TTM
-3883.89%
Revenue TTM
603.7M
Revenue Per Share TTM
5.17
Quarterly Revenue Growth YOY
30.9%
Gross Profit TTM
293.2M
EBITDA
-401.6M
Diluted Eps TTM
-3.92
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.13
EPS Estimate Next Year
-2.76
EPS Estimate Current Quarter
-0.85
EPS Estimate Next Quarter
-0.81

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 30 Wall street analysts offering stock ratings for Guardant Health, Inc.(by analysts ranked 0 to 5 stars)
Based on 30 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
25
25
25
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 11.74%

Current $32.55
Target $36.37

Company Financials

FY18Y/Y Change
Revenue
90.6M
↑ 81.85%
Net Income
-85.1M
↑ 2.21%
Net Profit Margin
-93.85%
↑ 73.12%
FY19Y/Y Change
Revenue
214.4M
↑ 136.52%
Net Income
-67.9M
↓ 20.23%
Net Profit Margin
-31.65%
↑ 62.2%
FY20Y/Y Change
Revenue
286.7M
↑ 33.75%
Net Income
-246.3M
↑ 262.98%
Net Profit Margin
-85.89%
↓ 54.24%
FY21Y/Y Change
Revenue
373.7M
↑ 30.32%
Net Income
-384.8M
↑ 56.23%
Net Profit Margin
-102.98%
↓ 17.09%
FY22Y/Y Change
Revenue
449.5M
↑ 20.31%
Net Income
-654.6M
↑ 70.12%
Net Profit Margin
-145.61%
↓ 42.63%
FY23Y/Y Change
Revenue
563.9M
↑ 25.45%
Net Income
-479.4M
↓ 26.76%
Net Profit Margin
-85.02%
↑ 60.59%
Q4 FY22Q/Q Change
Revenue
126.9M
↑ 8.08%
Net Income
-139.9M
↓ 13.62%
Net Profit Margin
-110.28%
↑ 27.7%
Q1 FY23Q/Q Change
Revenue
128.7M
↑ 1.44%
Net Income
-133.5M
↓ 4.57%
Net Profit Margin
-103.74%
↑ 6.54%
Q2 FY23Q/Q Change
Revenue
137.2M
↑ 6.55%
Net Income
-72.8M
↓ 45.5%
Net Profit Margin
-53.06%
↑ 50.68%
Q3 FY23Q/Q Change
Revenue
143.0M
↑ 4.29%
Net Income
-86.1M
↑ 18.32%
Net Profit Margin
-60.2%
↓ 7.14%
Q4 FY23Q/Q Change
Revenue
155.1M
↑ 8.41%
Net Income
-187.0M
↑ 117.23%
Net Profit Margin
-120.63%
↓ 60.43%
Q1 FY24Q/Q Change
Revenue
168.5M
↑ 8.67%
Net Income
-115.0M
↓ 38.52%
Net Profit Margin
-68.24%
↑ 52.39%
FY18Y/Y Change
Total Assets
587.4M
↑ 71.29%
Total Liabilities
62.5M
↑ 81.9%
FY19Y/Y Change
Total Assets
962.5M
↑ 63.86%
Total Liabilities
114.5M
↑ 83.41%
FY20Y/Y Change
Total Assets
2.3B
↑ 136.02%
Total Liabilities
916.2M
↑ 699.87%
FY21Y/Y Change
Total Assets
2.2B
↓ 2.96%
Total Liabilities
1.6B
↑ 70.22%
FY22Y/Y Change
Total Assets
1.6B
↓ 26.97%
Total Liabilities
1.5B
↓ 0.62%
FY23Y/Y Change
Total Assets
1.8B
↑ 10.96%
Total Liabilities
1.6B
↑ 5.03%
Q4 FY22Q/Q Change
Total Assets
1.6B
↓ 5.39%
Total Liabilities
1.5B
↑ 0.96%
Q1 FY23Q/Q Change
Total Assets
1.5B
↓ 6.11%
Total Liabilities
1.6B
↑ 0.41%
Q2 FY23Q/Q Change
Total Assets
1.8B
↑ 21.72%
Total Liabilities
1.5B
↓ 0.57%
Q3 FY23Q/Q Change
Total Assets
1.8B
↓ 2.33%
Total Liabilities
1.6B
↑ 1.4%
Q4 FY23Q/Q Change
Total Assets
1.8B
↓ 0.6%
Total Liabilities
1.6B
↑ 3.75%
Q1 FY24Q/Q Change
Total Assets
1.7B
↓ 4.58%
Total Liabilities
1.6B
↑ 0.53%
FY18Y/Y Change
Operating Cash Flow
-72.2M
↓ 0.07%
Investing Cash Flow
-153.0M
↓ 10.2%
Financing Cash Flow
293.2M
↑ 4.08%
FY19Y/Y Change
Operating Cash Flow
-47.1M
↓ 34.7%
Investing Cash Flow
-317.6M
↑ 107.52%
Financing Cash Flow
367.3M
↑ 25.29%
FY20Y/Y Change
Operating Cash Flow
-103.9M
↑ 120.49%
Investing Cash Flow
-617.1M
↑ 94.31%
Financing Cash Flow
1.4B
↑ 283.96%
FY21Y/Y Change
Operating Cash Flow
-209.0M
↑ 101.12%
Investing Cash Flow
-63.2M
↓ 89.77%
Financing Cash Flow
-66.8M
↓ 104.74%
FY22Y/Y Change
Operating Cash Flow
-309.5M
↑ 48.06%
Investing Cash Flow
149.8M
↓ 337.22%
Financing Cash Flow
-189.1M
↑ 182.97%
Q4 FY22Q/Q Change
Operating Cash Flow
-90.7M
↑ 16.11%
Investing Cash Flow
70.6M
↑ 71.12%
Financing Cash Flow
2.3M
↓ 112.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-74.4M
↓ 17.97%
Investing Cash Flow
157.2M
↑ 122.61%
Financing Cash Flow
-854.0K
↓ 136.84%
Q2 FY23Q/Q Change
Operating Cash Flow
-94.0M
↑ 26.29%
Investing Cash Flow
-241.1M
↓ 253.37%
Financing Cash Flow
383.9M
↓ 45047.78%

Technicals Summary

Sell

Neutral

Buy

Guardant Health, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Guardant Health, Inc.
Guardant Health, Inc.
8.72%
37.4%
-14.07%
-72.14%
-65.25%
Agilent Technologies Inc.
Agilent Technologies Inc.
-1.04%
2.33%
11.66%
-9.54%
90.36%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-1.42%
-5.48%
-9.32%
-25.83%
71.29%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-2.48%
1.95%
5.99%
6.41%
88.97%
Danaher Corp.
Danaher Corp.
-2.43%
11.02%
4.34%
-11.45%
75.7%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
8.2%
8.02%
2.7%
-4.72%
46.42%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Guardant Health, Inc.
Guardant Health, Inc.
NA
NA
NA
-3.13
-38.84
-0.17
NA
0.56
Agilent Technologies Inc.
Agilent Technologies Inc.
31.64
31.64
2.7
5.21
0.21
0.08
0.01
21.31
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.31
48.31
4.75
11.07
0.72
0.23
NA
18.93
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.58
35.58
2.81
21.71
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
46.26
46.26
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.46
31.46
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Guardant Health, Inc.
Guardant Health, Inc.
Buy
$4.1B
-65.25%
NA
-76.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.7B
90.36%
31.64
18.84%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.3B
71.29%
48.31
23.26%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$212.0B
88.97%
35.58
14.2%
Danaher Corp.
Danaher Corp.
Buy
$186.8B
75.7%
46.26
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.4B
46.42%
31.46
9.01%

Insights on Guardant Health, Inc.

  • Increasing Revenue

    Revenue is up for the last 9 quarters, 96.09M → 168.49M (in $), with an average increase of 6.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -187.04M → -114.98M (in $), with an average increase of 62.7% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 11.7% return, outperforming this stock by 25.8%

  • Vs TMO

    In the last 3 years, Guardant Health, Inc. has experienced a drawdown of -72.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 61.9%

Institutional Holdings

  • Vanguard Group Inc

    9.35%
  • BlackRock Inc

    9.00%
  • Baillie Gifford & Co Limited.

    5.09%
  • Deep Track Capital, LP

    4.90%
  • Cadian Capital Management LP

    4.73%
  • Eventide Asset Management, LLC

    3.42%

Corporate Announcements

  • Guardant Health, Inc. Earnings

    Guardant Health, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Organization
Guardant Health, Inc.
Employees
1768
CEO
Dr. Helmy Eltoukhy Ph.D.
Industry
Health Services

FAQs